LABORATORY PRODUCTS
Clean Room
Compact cleanroom, precision airfl ow
Regulatory-ready live-cell platform for GMP environments
Agilent has upgraded its xCELLigence RTCA eSight system with new software that meets 21 CFR Part 11 compliance, opening the door for its use beyond research labs into GMP- regulated manufacturing and quality control.
The enhanced platform now supports secure user authentication, electronic signatures, and full audit trails, ensuring that data generated in live-cell experiments is both trustworthy and regulatory-ready. This allows researchers and manufacturers to rely on a single system throughout the drug development pipeline — from early discovery to cell therapy production — reducing variability, saving time, and
streamlining compliance.
“Adding Part 11 compliance to the RTCA eSight means our customers can trust their data for both scientifi c insight and regulatory submissions,” said Dr Knut Wintergerst, VP and GM of Agilent’s Cell and
Biomolecular Analysis Division. “It strengthens Agilent’s role as a partner across discovery and GMP-regulated environments.”
By bridging research and production, the upgraded RTCA eSight provides a unifi ed, audit-secure solution that meets the rising
demand for digital lab tools in biopharma and cell therapy manufacturing.
More information online:
ilmt.co/PL/8epN and
ilmt.co/PL/ZO9b
66314pr@reply-direct.com ADVERTORIAL
Working with dirty or offgassing components in a clean room can be a challenge. Some industrial and R&D applications require both a particle-free environment and handling of materials that emit particles or gases.
To meet this need, Spetec® has developed
the Flow Box EFBS - a laminar fl ow box with an integrated, acid-resistant extraction unit. What sets the EFBS apart is its side- mounted extraction system connected to a universally adjustable telescopic arm. The arm’s tip can be positioned with pinpoint precision to capture particles or gases at the source, while the component itself remains bathed in fi ltered air. Extraction rates are continuously adjustable, up to 1.2 m³/min.
A single Flow Box EFBS creates an effective clean room area of 0.37–1.12 m², which is often suffi cient for many tasks. Its Type H14 fi lter removes at least 99.995% of particles (0.12 μm, MPPS), improving air quality in the workspace by over 10,000 times compared with ambient air - achieving ISO class 5 standards without any building work.
The Flow Box EFBS is built from high-quality materials, including acrylic glass and anodised aluminium, ensuring durability and safety in demanding environments.
More information online:
ilmt.co/PL/vlz6 66513pr@reply-direct.com
You don’t adapt to your CDMO partner, we adapt to you
When it comes to liquid formulations and freeze-drying CDMO services, fl exibility is key. Biopharma Group offers this fl exibility by tailoring solutions to meet the unique needs of each customer. Whether it’s optimising formulations, scaling up production, or navigating complex freeze-drying, aka lyophilisation, processes, we work closely with customers to deliver results that align with their goals.
In the fast-paced world of pharma, diagnostics, and biotech, adaptability is increasingly a necessity. You can’t afford to be constrained by a one-size-fi ts-all approach; you need a CDMO partner who will collaborate to offer the integrated solutions that best suit you, and your products. At Biopharma Group, we understand this, which is why our CDMO division is built on the principle of fl exibility; we don’t expect you to adapt to us; we adapt to you.
Whether you’re a small biotech startup requiring nimble support for refi ning a critical clinical formulation, an R&D Manager
overseeing complex lyophilisation processes or a large pharmaceutical company seeking effi cient scale-up for a blockbuster drug, by partnering with Biopharma Group, you gain access to a team of experienced scientists with unmatched lyo expertise. Using a collaborative approach ensures that your project receives the dedicated attention it deserves, while benefi ting from Biopharma Group’s extensive resources and industry knowledge. In a world of constant change, choosing a CDMO partner that prioritises adaptability, and scalability is crucial for success. Biopharma Group offers that assurance, empowering you to focus on what matters most: developing life-changing therapies.
From formulation development to scale-up, tech transfer and product delivery, our team collaborates closely with you every step of the way, whilst you retain IP ownership and control of your products throughout the process. Don’t compromise on your vision, choose a CDMO partner that prioritises your needs.
Contact Biopharma Group today to discuss your CDMO requirements.
More information online:
ilmt.co/PL/WDeZ 66497pr@reply-direct.com
Cell Analysis
Get all the latest news direct to your inbox!
WWW.LABMATE-ONLINE.COM
59
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
